NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Just my 2 cents….I'll explain my thinking more tomorrow, but research concludes the mesenchymal subgroup also responds well (not as well as it does to DCVAX) to "aggressive" chemo/radiation therapy. The key in the present DCVAX-L trial is that all tumors at baseline are stable due to trial design, and DCVAX-L has an overall more synergistic effect in this case. Regardless, IMHO, even if the trial design did not have the above feature, we'd still meet the endpoints.